WAM
SUPN icon

Wolverine Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Wolverine Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-191
Closed -$20K – 2534
2014
Q1 		$20K Buy
+191
New +$1.76K ﹤0.01% 1632
2013
Q4 		– Sell
-531
Closed -$26K – 2921
2013
Q3 		$26K Buy
+531
New +$3.57K ﹤0.01% 1952

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Wolverine Asset Management's SUPN Position: Q4 2019 in Review

Wolverine Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2019, closing a stake of 1,705 shares — an estimated $41.4K sold.

Wolverine Asset Management first reported a position in SUPN in Q2 2013 and held it in 13 quarters. The position peaked at $854K in Q2 2013. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

  • Wolverine Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Wolverine Asset Management sold 1,705 Supernus Pharmaceuticals shares in Q4 2019, an estimated $41.4K.
  • Wolverine Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Wolverine Asset Management's Supernus Pharmaceuticals position peaked at $854K in Q2 2013.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on Wolverine Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.